# New solution meets changing needs amid GLP-1 demand

Evernorth EncircleRx<sup>™</sup>: Cardiodiabesity helps manage costs, improve outcomes and prevent fraud

### After years of rising obesity rates, could <u>glucagon-like</u> <u>peptide-1 (GLP-1)</u> agonists reverse the trend?

The question comes as two in five U.S. adults have obesity.<sup>1</sup> This means their body mass index (BMI) is 30 or higher. Obesity causes a variety of chronic conditions, including diabetes and cardiovascular disease.

The U.S. Food and Drug Administration (FDA) approved Ozempic perhaps the best-known GLP-1—in 2017 to treat diabetes. More recently, doctors have prescribed GLP-1s to help people lose weight. The FDA approved <u>Wegovy</u> and Zepbound, in 2021 and 2023 respectively, for weight loss.



Doctors have prescribed GLP-1s to treat diabetes for



# As GLP-1 use increases, plan sponsors need a solution that can manage costs and help patient outcomes.

It should also ensure GLP-1s stay available for patients who need them. The <u>EncircleRx: Cardiodiabesity program</u> addresses these needs.

					· ·	
+	+	+	+	+	+	+
+	+	+	+	+	+	+



### Promoting better outcomes

EncircleRx helps patients reach their goals by engaging them in the Omada for Prevention program. Lifestyle management programs like Omada support healthy habits for weight management. They feature food and activity coaching, behavioral health support, education, digital tools and outreach.

Omada combines human-led coaching with data-driven insights, clinical intervention and guidance through member action with significant results. **In the last six months, EncircleRx members netted the following results from the Omada program:** 



**4.8%** average decrease in EncircleRx members' BMI<sup>2</sup>



**80%** of patients have gone above and beyond their program engagement benchmarks

These statistics show how GLP-1s and lifestyle modification programs can combine to aid in weight loss —making them vital in improving outcomes for patients.

#### Keeping medications available

A solution can help avoid GLP-1 shortages by ensuring proper prescribing, filling and adherence. To this end, monitoring and fraud protection are key.

### This starts with focusing on the most common forms of fraud.

- + Among members, it may be stockpiling medications or seeing more than one doctor—also known as "doctor-shopping".
- + Among prescribers, it may be misrepresenting prior authorization or forging lab results.
- + Among both groups, it may be getting prescription medication for illegal purposes—a practice called diversion.

Since launching, EncircleRx has saved clients nearly

### \$200 million

in plan savings.

## Solution debuts with strong results

Launched in May 2024, EncircleRx has enrolled more than 9 million people in its weight loss and diabetes program enrollment continues to grow month-over-month. This strong response shows the need for a data-driven solution amid rising GLP-1 demand.

The solution saves plan costs by identifying patients who need treatment.





#### Guarding against GLP-1 fraud

EncircleRx has high standards for fraud prevention. Here are some ways it guards against it:

- Reaching out to prescribers to raise awareness about inappropriate medication prescribing or use.
- 2 Using targeted analytics to point out prescriber and member fraud, waste, and abuse as well as members who don't adhere to the program.
- 3 Investigating allegations as needed.
- Blocking prescribers at pharmacy points of sale to ensure proper patient-prescriber relationships.

#### Fraud protection measures

EncircleRx fraud protection measures produced significant results within the first six months.

EncircleRx also conducts prescriber and member investigations. Since launch, these investigations have increased 4-fold and continues to trend upwards.

One investigation resulted in a case being reported to the FBI. Through advanced analytics, targeted outreach and active monitoring EncircleRx has curbed inappropriate prescriber behavior.

After outreach was sent explaining what EncircleRx was doing to deter fraudulent prescribing to more than 250 prescribers it found to be "high-risk,"

### GLP-1 prescribing decreased by roughly 18%

among the group.






# Gaining peace of mind

As GLP-1 use becomes more common, plan sponsors will want to address cost management, accessibility and lifestyle modification program options that meet the needs of plan sponsors. In addition, they will want a robust fraud, waste and abuse program to ward off the potential for misuses.

Plan sponsors should look for a solution that can help control costs. The solution should offer tools to help patients lose weight and live healthier lives. It should also offer robust fraud protection by monitoring potential fraud among providers and members.



- 1. CDC, 2024. https://www.cdc.gov/obesity/adult-obesity-facts
- 2. Results at first year of Omada program participation.

All Evernorth Health Services products and services are provided exclusively by or through affiliates of the Evernorth companies, including Evernorth Care Solutions, Inc., Evernorth Behavioral Health, Inc., Evernorth Behavioral Health of Texas, Inc. and Evernorth Behavioral Health of California, Inc.

**EVERNORTH**<sup>\*</sup> HEALTH SERVICES

© 2025 Evernorth Health Services. All rights reserved. Some content provided under license.